Ecovia Bio To Expand Manufacturing Capacity

Ecovia Bio, a biotechnology company specializing in sustainable, high-performance biopolymer ingredients, will expand its manufacturing capacity with the closure of a Series B funding round led by Detroit-based independent angel investor group Pointe Angels.

The funding will support significant expansion of manufacturing capacity at Ecovia Bio’s Livonia facility to meet surging global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid (γ-PGA) and specialty biopolymer products across cosmetics, personal care, agriculture and hygiene applications.

Addressing Microplastics Concerns

Officials say global environmental and health imperative microplastics have emerged as one of the most pressing environmental and public health challenges of our time. Superabsorbent polymers (SAPs) – synthetic, petrochemical-derived plastics used extensively in diapers, feminine hygiene products, cosmetics, lotions and other consumer goods – persist in landfills for centuries and fragment into harmful microplastics that contaminate soil, water systems and the food chain. These microplastics have been detected in human blood, lungs and placental tissue, raising serious health concerns.

Ecovia Bio’s biodegradable γ-PGA technology represents a transformative solution, enabling manufacturers to replace these persistent synthetic polymers with a bio-based, fully biodegradable alternative that delivers equivalent or superior performance without environmental or health consequences. By scaling production of γ-PGA, Ecovia Bio says it’s empowering a global shift toward truly sustainable consumer products – addressing regulatory pressures, consumer demand for safer products and the urgent need to protect human health and environmental integrity.

Ecovia Bio’s products are designed to reduce dependence on petrochemicals while delivering “superior performance” in demanding applications, officials say.